TY  - RPRT
TI  - The human-specific RPGR isoform RPGRs14/15 and the clinically approved Rho/ROCK inhibitor Ripasudil represent therapeutic options to address RPGR-associated defects.
AU  - Usman, M.
AU  - Atigbire, P.
AU  - Kastrati, D.
AU  - Brinkhoff, J. M.
AU  - Kluth, C.
AU  - Marticke, J.
AU  - Jueschke, C.
AU  - Neidhardt, J.
PY  - 2025
DO  - 10.1101/2025.05.09.653106
UR  - https://www.biorxiv.org/content/10.1101/2025.05.09.653106v1
ID  - 10.1101/2025.05.09.653106
ER  -